ixchiq vaccine fda - Search News

News

FDA Suspends Valneva Vaccine's License

MedCity News · 1h

FDA Suspends Valneva Vaccine’s License Following New Reports of Adverse Events

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a pause on dosing of Ixchiq, but the agency’s new safety alert is based on an assessment that found the vaccine appears to be causing chikungunya-like illness in recipients.

MedPage Today on MSN · 19h

In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events that happened outside the U.S., three of which were in people ages 70 to 82 years and the other in a 55-year-old individual.

Medical Dialogues · 1h

USFDA Suspends Ixchiq Chikungunya Vaccine License Citing Encephalitis Death, 20+ Serious Adverse Events

The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), manufactured by Valneva Austria GmbH, following serious

1h

Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results